Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study.
BRCA
BRCA mutation
Ovarian cancer
PARPi
olaparib
platinum
relapsed ovarian cancer
routine clinical practice
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
05
09
2022
revised:
24
11
2022
accepted:
07
12
2022
entrez:
25
1
2023
pubmed:
26
1
2023
medline:
28
1
2023
Statut:
ppublish
Résumé
Olaparib was approved in 2014 by the European Medicines Agency (EMA) as maintenance treatment for patients with breast cancer gene (BRCA)-mutated platinum-sensitive relapsed high-grade epithelial ovarian cancer (EOC) following the results of the Study 19. We present the results of a national real-world study on the effectiveness of olaparib in relapsed BRCA-mutated EOC patients. Patients with EOC, peritoneal, and/or fallopian-tube cancer treated with olaparib in a French Center between May 2014 and March 2017 were included. The primary end-point of the study was progression-free survival. Of the 128 patients analyzed, 89 were treated according to the EMA label. The median progression-free survival was 17.0 months. The most common treatment-related toxicity was fatigue. Treatment-related myelodysplastic syndrome (n=5) and a second cancer (n=1) were diagnosed. In this real-life setting, olaparib confirmed its efficacy and safety profile, as previously shown in clinical trials.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Olaparib was approved in 2014 by the European Medicines Agency (EMA) as maintenance treatment for patients with breast cancer gene (BRCA)-mutated platinum-sensitive relapsed high-grade epithelial ovarian cancer (EOC) following the results of the Study 19. We present the results of a national real-world study on the effectiveness of olaparib in relapsed BRCA-mutated EOC patients.
PATIENTS AND METHODS
METHODS
Patients with EOC, peritoneal, and/or fallopian-tube cancer treated with olaparib in a French Center between May 2014 and March 2017 were included. The primary end-point of the study was progression-free survival.
RESULTS
RESULTS
Of the 128 patients analyzed, 89 were treated according to the EMA label. The median progression-free survival was 17.0 months. The most common treatment-related toxicity was fatigue. Treatment-related myelodysplastic syndrome (n=5) and a second cancer (n=1) were diagnosed.
CONCLUSION
CONCLUSIONS
In this real-life setting, olaparib confirmed its efficacy and safety profile, as previously shown in clinical trials.
Identifiants
pubmed: 36697069
pii: 43/2/653
doi: 10.21873/anticanres.16202
doi:
Substances chimiques
Antineoplastic Agents
0
olaparib
WOH1JD9AR8
Phthalazines
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
653-662Informations de copyright
Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.